Follow us on Twitter
twitter icon@FreshPatents


Therapeutics patents

      

This page is updated frequently with new Therapeutics-related patent applications.




 Neutralizing antibodies and methods of use thereof patent thumbnailNeutralizing antibodies and methods of use thereof
This invention provides monoclonal antibodies that recognize the toll-like receptor 4/md-2 receptor complex, and monoclonal antibodies that recognize the tlr4/md2 complex as well as tlr4 when not complexed with md-2. The invention further provides methods of using the humanized monoclonal antibodies as therapeutics.
Novimmune Sa


 Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics patent thumbnailPolypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against krtcap3, fam26f, mgc52498, fam70a or tmem154 antigens, which are differentially expressed in cancer, and diagnostic and therapeutic usages.
Compugen Ltd


 Inhibitors of late sv40 factor (lsf) as cancer chemotherapeutics patent thumbnailInhibitors of late sv40 factor (lsf) as cancer chemotherapeutics
The present invention is directed to methods, compositions and kits for treatment of cancer, e.g. Heptacellular carcinoma.
Trustees Of Boston University


 Composition for improving stability of stem cells patent thumbnailComposition for improving stability of stem cells
The present invention relates to a composition capable of improving storage stability of stem cells. More specifically, the present invention relates to a composition which contains a serum or a plasma for improving cold storage stability of stem cells.

 Gamma-aa-peptide stat3/dna inhibitors and methods of use patent thumbnailGamma-aa-peptide stat3/dna inhibitors and methods of use
Stat3 hyperphosphorylation, dimerization and dna binding are required for its ability to contribute to malignant transformation. As such, stat3 has been recognized as a promising target for cancer therapy.
University Of South Florida


 In vitro model for neuronal death patent thumbnailIn vitro model for neuronal death
This invention demonstrates the formation of a novel polarized membrane lipid raft signaling module in neurons, in response to several diverse neurotoxic stimuli. This polarization occurs well before neurons commit to die, and is an early mechanism in death signaling.

 Combinations of cancer therapeutics patent thumbnailCombinations of cancer therapeutics
The invention relates to combinations of 4-[(s)-2-azetidin-1-yl-1-(4-chloro-3-trifluoromethyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide and/or its physiologically acceptable salts and solvates, and an inhibitor of her2, and the use of such combinations for the treatment of cancer.. .
Merck Patent Gmbh


 Immunoglobulin-bound extracellular vesicles and uses thereof patent thumbnailImmunoglobulin-bound extracellular vesicles and uses thereof
Provided are methods of isolating igg-bound (e.g., igg-bound or protein g-recognized igg-bound) extracellular vesicles from a sample containing a biological fluid from a subject, where the igg (e.g., igg2 or protein g-recognized igg) is bound to an antigen present on the surface of the extracellular vesicle and the igg (e.g., igg2 or protein g-recognized igg) is an endogenous antibody. Also provided are methods of diagnosing a cancer in a subject that include detecting the presence of one or more tumor antigens in an isolated igg-bound (e.g., igg2-bound or protein g-recognized igg-bound) extracellular vesicle, and methods of treating a subject that include administering one or more cancer therapeutics to a subject having an igg-bound (e.g., igg2-bound or protein g-recognized igg-bound) extracellular vesicle that contains one or more tumor antigens..
University Of Louisville Research Foundation, Inc.


 Compositions and methods for inhibiting gene expression of lpa patent thumbnailCompositions and methods for inhibiting gene expression of lpa
Rna interference (rnai) agents and rnai agent conjugates for inhibiting the expression of the lpa (apo(a)) gene are described. Pharmaceutical compositions comprising one or more lpa rnai agents optionally with one or more additional therapeutics are also described.
Arrowhead Pharmaceuticals, Inc.


 Improved peptide pharmaceuticals for insulin resistance patent thumbnailImproved peptide pharmaceuticals for insulin resistance
Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics..
Mederis Diabetes, Llc


Antimicrobial articles produced by additive manufacturing

An antibiotic-eluting article for implantation into a mammalian subject, produced by an additive manufacturing process wherein a polymeric material is concurrently deposited with a selected antibiotic. The additive manufacturing process may be a selective laser sintering process or a selective laser melting process or a selective heat sintering process or an electron beam melting process.
Orthopaedic Innovation Centre

Oligonucleic acid variant libraries and synthesis thereof

Disclosed herein are methods for the generation of highly accurate oligonucleic acid libraries encoding for predetermined variants of a nucleic acid sequence. The degree of variation may be complete, resulting in a saturated variant library, or less than complete, resulting in a selective library of variants.
Twist Bioscience Corporation

Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapy

Low-molecular weight gadolinium (gd)-based mr contrast agents for psma-specific ti-weighted mr imaging are disclosed. The (gd)-based mr contrast agents exhibit high binding affinity for psma and exhibit specific ti contrast enhancement at psma+ cells.
Northwestern University

Highly soluble aquaporin-4 extracellular loop c peptide immunization for treatment of neuromyelitis optica

The present invention provides pharmaceutical compositions for treating neuromyelitis optica (nmo) comprising a therapeutically effective amount of loop c sequence-containing peptide of aquaporin-4 (aqp4) water channel, or a therapeutically effective fragment or variant thereof. The invention also provides methods for treating nmo by administering therapeutically effective amounts of loop c sequence-containing peptide(s) of aqp4, optionally in an immunosuppressive setting, and also provides diagnostics for detection of nmo in a subject, screening methods for identification of nmo-treating therapeutics and nmo model systems..
The Johns Hopkins University

Methods and systems of assessing tissue vascular permeability using non-labeled dextran

A method of assessing tissue vascular permeability for nanotherapeutics using non-labeled dextran can include: receiving a non-labeled, physiologically-tolerable dextran solution by a subject; acquiring a plurality of magnetic resonance images of a distribution of the dextran solution within at least one region of interest of the subject for a corresponding plurality of times; and assessing a tissue vascular permeability of the at least one region of interest to dextran particles in the dextran solution based on differences between the plurality of magnetic resonance images, wherein the dextran solution is a substantially mono-disperse solution of dextran particles of one size.. .
The Johns Hopkins University

Identification of novel diagnostics and therapeutics by modulating rhoh

The disclosure relates to identifying novel therapeutic targets and/or diagnostic and/or prognostic markers by correcting abnormal rhoh expression in a hematopoietic cell.. .
Leukemia Therapeutics, Llc

High-throughput single cell sorting using microbubble well arrays

The present invention provides a microfabricated device and methods for high throughput single cell screening of a heterogeneous population. The present invention is partly based upon but not limited to sorting by monitoring cell secreted factors that accumulate in time (hours, days, weeks) as cells are cultured in the microbubble well niche the architecture of which facilitate the accumulation.
Nidus Biosciences, Llc

Medication adherence monitoring device

A self monitoring and reporting therapeutics, smart® composition, method, apparatus and system are provided which flexibly provide options, by combining different embodiments of the device with different embodiments of the composition, the ability to conduct definitive medication adherence monitoring over the short term (acute medication adherence monitoring, immediately up to an hour or so after taking a medication), intermediate term (intermediate medication adherence monitoring, imam, an hour or so to a day or so after taking a medication), and longer term (chronic medication adherence monitoring, cmam, a day to several days after taking a medication).. .
Xhale, Inc.

Methods for treating cancer resistant to erbb therapeutics

Provided herein are methods for treating cancer that is resistant to treatment with an anti-erbb therapeutic agent and which is associated with an activating met gene mutation or a met gene amplification. The methods involve administering to a subject a combination of an anti-erbb therapeutic and an anti-met therapeutic.
The General Hospital Corporation D/b/a Massachusetts General Hospital

Methods and products for transfection

The present invention relates in part to methods for producing tissue-specific cells from patient samples, and to tissue-specific cells produced using these methods. Methods for reprogramming cells using rna are disclosed.
Factor Bioscience Inc.

Method for identifying and validating dominant t helper cell epitopes using an hla-dm-assisted class ii binding assay

Rational design of immunotherapeutics relies on clear knowledge of the immunodominant epitopes of antigens. Current methods for identifying kinetically stable peptide-mhc complexes are in many cases inadequate for a number of reasons.
The Johns Hopkins University

Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses

The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, alzheimer's disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, syndrome x, thrombotic disorder. Compounds and methods of the invention can also be used to modulate c reactive protein or enhance bile production in a patient.
Esperion Therapeutics, Inc.

Mesothelin vaccines and model systems

Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic t cell response.
The Johns Hopkins University

Compositions and methods for drug-sensitization or inhibition of a cancer cell

The disclosure provides rifamycin and rifamycin derivative compositions, including rifabutin and rifabutin derivative compositions able to cause drug-sensitization in a cancer cell or inhibition of a cancer cell. The disclosure also provides methods of administering such compositions to cancer cells to sensitize them to drugs, such as chemotherapeutics, or directly inhibit them.
The Texas A&m University System

Compounds for treating ophthalmic diseases and disorders

The present invention relates generally to the field of ocular therapeutics and the development thereof for use in humans or animals. More particularly, it relates to dhodh inhibitor compounds and their use for the treatment of ophthalmic diseases and disorders.
Panoptes Pharma Ges.m.b.h.

Method of delivering therapeutics and imaging agents to the brain by nanoparticles that cross the blood brain barrier

Described herein are methods of delivering a nanoparticle across the blood brain barrier to the brain of a subject by administering to the subject a nanoparticle having a nanoparticle core and a targeting agent. A variety of targeting agents may serve to promote delivery of the described nanoparticle..
California Institute Of Technology

Systems and methods for clonal replication and amplification of nucleic acid molecules for genomic and therapeutic applications

The present invention provides for methods, reagents, apparatuses, and systems for the replication or amplification of nucleic acid molecules from biological samples. In one embodiment of the invention, the nucleic molecules are isolated from the sample, and subjected to fragmenting and joining using ligating agents of one or more hairpin structures to each end of the fragmented nucleic molecules to form one or more dumbbell templates.
Redvault Biosciences, Lp

Erythrocyte-binding therapeutics

Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes.
École Polytechnique Fédérale De Lausanne (epfl)

Nucleotide and amino acid sequences relating to respiratory diseases and obesity

This invention relates to genes identified from human chromosome 12q23-qter, which are associated with various diseases, including asthma. The invention also relates to the nucleotide sequences of these genes, isolated nucleic acids comprising these nucleotide sequences, and isolated polypeptides or peptides encoded thereby.
Oscient Pharmaceuticals Corporation

Heterodimeric proteins and methods for producing and purifying them

The present invention relates to engineered heteromultimeric proteins, and more specifically, to methods for producing and purifying heterodimeric proteins, such as bispecific antibodies and other heterodimeric proteins comprising immunoglubulin-like hinge sequences. Methods for producing and purifying such engineered heterodimeric proteins and their use in diagnostics and therapeutics are also provided..
Rinat Neuroscience Corp.

Monoclonal antibodies for treatment of cancer

The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing gt468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, and hepatocellular cancer.. .
Johannes Gutenberg-universität Mainz

Pd-l1 antibodies

The present invention relates to antibodies that bind human programmed cell death 1 ligand 1 (pd-l1), and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and other cancer therapeutics.. .
Eli Lilly And Company

Targeted therapeutics

The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds.
Synta Pharmaceuticals Corp.

Targeted therapeutics

The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds.
Synta Pharmaceuticals Corp.

Amphiphilic drug-drug conjugates for cancer therapy, compositions and methods of preparation and uses thereof

The invention provides novel amphiphilic drug-drug conjugates useful as cancer therapeutics, and compositions and methods thereof.. .
Shanghai Jiao Tong University

Ghrelin o-acyltransferase inhibitors

Small molecule ghrelin o-acyltransferase inhibitors found using an assay to detect ghrelin o-acyltransferase activity using an acrylodan-labeled peptide mimic of ghrelin that provides for high-throughput screening for ghrelin o-acyltransferase inhibitors and detection via high performance liquid chromatography. The newly discovered class of synthetic triterpenoids efficiently inhibits ghrelin acylation by goat and function as covalent reversible inhibitors of goat.
Syracuse University

Polythioaminals and uses thereof

Wherein each r1 is independently an organic or hetero-organic group, each r2 is independently a substituent having molecular weight no more than about 120 daltons, x and z are each a sulfur-bonded species, at least one of x and z is not hydrogen, and n is an integer greater than or equal to 1. X and z may be hydrogen or a functional group, such as a thiol-reactive group.

Targeted therapeutics

The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds.
Synta Pharmaceuticals Corp.

Influenza antigen delivery vectors and constructs

The present invention relates to fluorocarbon vectors for the delivery of influenza antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-influenza antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals, including humans..
Altimmune Uk Limited

Combination therapy of anti-mif antibodies and chemotherapeutics

The present invention pertains to anti-mif antibodies, in particular their use in combination with cancer therapeutics, i.e. Chemotherapeutics, in the treatment of cancer..
Baxalta Gmbh

Method for medical treatment

The disclosure provides improved methods for treating or preventing a class of undesired health events including multiple related maladies, such as a disease, condition, or syndrome or the like. The improvement results from optimization of energy metabolism by administering a therapeutically effective compound selected to a) modulate mitochondrial activity to correct for deficiencies resulting from the disease, b) to boost cell energy metabolism thereby improving the original method's efficacy, and/or c) to correct for metabolic disruptions resulting from therapies or medicaments used in the method to be improved.

Method of treating inflammation, allergy and asthma with a purified extract (atc1) isolated from pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient

The present invention relates to inventive novel industrialized method for preparing purified extract containing more abundant active ingredients such as catalpol derivatives from the extract of pseudolysimachion rotundum var subintegrum than that prepared by the conventional preparation method disclosed in the prior art and the therapeutics or functional health food comprising the purified extract for treating and preventing inflammatory, allergic or asthmatic disease. The purified extract showed more potent anti-inflammatory, anti-allergy and anti-asthma activity than that prepared by the conventional preparation method disclosed in the prior art through various in vivo tests such as inhibition test on the reproduction of eosinophil, the release of immunoglobulin and inflammatory chemokines in plasma and bronchoalveolar fluid as well as the suppression of airway hyperresponsiveness and goblet cell hyperplasia in a ova-sensitized/challenged mouse model..
Korea Research Institute Of Bioscience And Biotechnology

Method of treating inflammation, allergy and asthma with a purified extract (atc2) isolated from pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient

The present invention relates to inventive novel industrialized method for preparing purified extract containing more abundant active ingredients such as catalpol derivatives from the extract of pseudolysimachion rotundum var subintegrum than that prepared by the conventional preparation method disclosed in the prior art and the therapeutics or functional health food comprising the purified extract for treating and preventing inflammatory, allergic or asthmatic disease. The purified extract showed more potent anti-inflammatory, anti-allergy and anti-asthma activity than that prepared by the conventional preparation method disclosed in the prior art through various in vivo tests such as inhibition test on the reproduction of eosinophil, the release of immunoglobulin and inflammatory chemokines in plasma and bronchoalveolar fluid as well as the suppression of airway hyperresponsiveness and goblet cell hyperplasia in a ova-sensitized/challenged mouse model..
Korea Research Institute Of Bioscience And Technology

Pd-1 antibodies

The present invention relates to antibodies that bind human programmed cell death 1 (pd-1), and may be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics.. .
Innovent Biologics, Inc.

Inhibitors of late sv40 factor (lsf) as cancer chemotherapeutics

The present invention is directed to methods, compositions and kits for treatment of cancer, e.g. Heptacellular carcinoma.
Trustees Of Boston University

Chimeric therapeutics, compositions, and methods for using same

Chimeric therapeutics are disclosed that include a modified viral core protein comprising at least one mutation or modification in an immunogenic epitope and a therapeutic agent. The therapeutic agent may be associated with the modified viral core protein and may be a nucleic acid, a protein, or a small molecule.
Biomed Realty, L.p.

Targeting of glycoprotein therapeutics

Methods of making ligand-decorated polymer conjugates of therapeutic glycoproteins are described. Improved targeting of glycoproteins to specific tissues is achieved by masking the natural carbohydrate and other surface determinants with high molecular weight polymers, such as, e.g., peg, polysialic acid, etc., which in turn are decorated with target-specific ligands.
Genzyme Corporation

Delivery of biologic therapeutics

Formulations and methods are disclosed which provide controlled, sustained release of a biologic therapeutic to a space within the body. More specifically, formulations comprising a plurality of hydrophilic polymer strands, and methods of forming and administering such formulations, are disclosed.
Abbott Cardiovascular Systems Inc.

Nanoparticulate compositions for targeted delivery of acid labile, lipophilic prodrugs of cancer chemotherapeutics and their preparation

In one embodiment, the present application discloses synthetic ldl nanoparticles comprising mixtures of components selected from the group consisting of phospholipids, triglycerides, cholesterol ester and free cholesterol; optionally further comprising an agent selected from the group consisting of natural antioxidants, ubiquinol and vitamin e, and methods for preparing the synthetic nanoparticles. The disclosed synthetic ldl nanoparticles are capable of selectively delivering lipophilic drugs and prodrugs to cellular targets expressing ldl receptors after intra venous injection..
Arbor Therapeutics, Llc

Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues

A method for at least one of characterizing, diagnosing and treating a neurological health issue in at least a subject, the method comprising: receiving an aggregate set of biological samples from a population of subjects; generating at least one of a microbiome composition dataset and a microbiome functional diversity dataset for the population of subjects; generating a characterization of the neurological health issue based upon features extracted from at least one of the microbiome composition dataset and the microbiome functional diversity dataset; based upon the characterization, generating a therapy model configured to correct the neurological health issue; and at an output device associated with the subject, promoting a therapy to the subject based upon the characterization and the therapy model.. .
Ubiome, Inc.

Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics

This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against vsig1, ildr1, loc253012, ai216611, c1orf32 or fxyd3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages.
Compugen Ltd.

Antibody therapeutics that bind cd147

There is disclosed compositions and methods relating to or derived from anti-cd147 antibodies. More specifically, there is disclosed fully human antibodies that bind cd147, cd147-binding fragments and derivatives of such antibodies, and cd147-binding polypeptides comprising such fragments.
Sorrento Therapeutics, Inc.

Sp35 antibodies and uses thereof

Endogenous sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous sp35 function, such anti-sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction.
Biogen Ma Inc.



Therapeutics topics:
  • Therapeutics
  • Antibodies
  • Hypertension
  • Inflammation
  • Immunotherapy
  • Monoclonal
  • Recombinant
  • Radiation Therapy
  • Desmoplastic
  • Hypertensive
  • Photodynamic Therapy
  • Oligodendrocyte
  • Nucleic Acids
  • Nucleic Acid
  • Differentiation


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Therapeutics for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Therapeutics with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.4632

    file did exist - file did put2541

    4 - 1 - 53